These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15713105)

  • 41. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
    Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
    Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
    Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
    Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process.
    McRae A; Martins RN; Fonte J; Kraftsik R; Hirt L; Miklossy J
    Exp Gerontol; 2007 Apr; 42(4):355-63. PubMed ID: 17140756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanobiosensors for in vitro and in vivo analysis of biomolecules.
    Salvador JP; Kreuzer MP; Quidant R; Badenes G; Marco MP
    Methods Mol Biol; 2012; 811():207-21. PubMed ID: 22042682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A turn of the sulfatide in Alzheimer's disease.
    Irizarry MC
    Ann Neurol; 2003 Jul; 54(1):7-8. PubMed ID: 12838515
    [No Abstract]   [Full Text] [Related]  

  • 50. A new controlled concept of immune-sensing platform for specific detection of Alzheimer's biomarkers.
    Ammar M; Smadja C; Giang Thi Phuong L; Azzouz M; Vigneron J; Etcheberry A; Taverna M; Dufour-Gergam E
    Biosens Bioelectron; 2013 Feb; 40(1):329-35. PubMed ID: 22981833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of biosensors to monitor the immune response.
    Swanson SJ; Mytych D; Ferbas J
    Dev Biol (Basel); 2002; 109():71-8. PubMed ID: 12434915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.
    Look GC; Jerecic J; Cherbavaz DB; Pray TR; Breach JC; Crosier WJ; Igoudin L; Hironaka CM; Lowe RM; McEntee M; Ruslim-Litrus L; Wu HM; Zhang S; Catalano SM; Goure WF; Summa D; Krafft GA
    Curr Alzheimer Res; 2007 Dec; 4(5):562-7. PubMed ID: 18220523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring an antibody affinity chromatography with a label-free optical biosensor technique.
    Proll G; Kumpf M; Mehlmann M; Tschmelak J; Griffith H; Abuknesha R; Gauglitz G
    J Immunol Methods; 2004 Sep; 292(1-2):35-42. PubMed ID: 15350510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-Antigen Interaction Dynamics Revealed by Analysis of Single-Molecule Equilibrium Fluctuations on Individual Plasmonic Nanoparticle Biosensors.
    Aćimović SS; Šípová-Jungová H; Emilsson G; Shao L; Dahlin AB; Käll M; Antosiewicz TJ
    ACS Nano; 2018 Oct; 12(10):9958-9965. PubMed ID: 30165019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Probing Antibody-Antigen Interactions.
    Yang G; Velgos SN; Boddapati SP; Sierks MR
    Microbiol Spectr; 2014 Feb; 2(1):AID-0010-2013. PubMed ID: 26082105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Alzheimer's disease and biological markers].
    Lacomblez L
    Psychol Neuropsychiatr Vieil; 2004 Sep; 2(3):225-6. PubMed ID: 15704277
    [No Abstract]   [Full Text] [Related]  

  • 57. Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease.
    Ayton S; James SA; Bush AI
    Cell Chem Biol; 2017 Oct; 24(10):1192-1194. PubMed ID: 29053948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scientists develop new biosensor to test for Alzheimer's disease.
    Potticary J
    Bioanalysis; 2014 Mar; 6(6):725. PubMed ID: 24829955
    [No Abstract]   [Full Text] [Related]  

  • 59. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases.
    Yagi H; Kusaka E; Hongo K; Mizobata T; Kawata Y
    J Biol Chem; 2005 Nov; 280(46):38609-16. PubMed ID: 16162499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A microfluidic culture platform for CNS axonal injury, regeneration and transport.
    Taylor AM; Blurton-Jones M; Rhee SW; Cribbs DH; Cotman CW; Jeon NL
    Nat Methods; 2005 Aug; 2(8):599-605. PubMed ID: 16094385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.